Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19. Other viral pneumonia COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 m
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Moderate to severe 2019-nCoV-infected patients Being at the age of 18 to 80 years Patients or authorized family members volunteered to participate in this study and signed informed consent. Both genders pulmonary involvement in CT scan PCR positive
Exclusion criteria
Exclusion criteria: Patient with elevated liver enzymes 3 time the upper limit of normal Patients who are participating in other drug clinical trials Patients with active pulmonary tuberculosis Patients with definite bacterial and fungal infections Pregnant or lactating women Patient with active thrombotic event
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Khalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed